Recombinant CX3CL1 (Quetmolimab Biosimilar) antibody
Quick Overview for Recombinant CX3CL1 (Quetmolimab Biosimilar) antibody (ABIN7581360)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
-
-
Expression System
- CHO Cells
-
Purpose
- Anti-CX3CL1 / Fractalkine Reference Antibody (quetmolimab)
-
Sequence
- QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYYIHWVKQA PGQGLEWIGW IYPGDGSPKF NERFKGRTTL TADKSTNTAY MLLSSLRSED TAVYFCATGP TDGDYFDYWG QGTTVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSNFGTQTY TCNVDHKPSN TKVDKTVERK CCVECPPCPA PPAAAPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK,DIQMTQSPSS LSASVGDRVT ITCRASGNIH NFLAWYQQKP GKAPKLLIYN EKTLADGVPS RFSGSGSGTD YTLTISSLQP EDFATYFCQQ FWSTPYTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
-
Characteristics
- Anti-CX3CL1 / Fractalkine Reference Antibody (quetmolimab) is expressed from CHO. The heavy chain type is huIgG2, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Purity
- >95 %
-
Isotype
- IgG2SA
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
Therapeutic Agents by Target and Mechanism: CX3CL1 antagonist
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- +4°C,-80°C
-
-
- CX3CL1 (Quetmolimab Biosimilar)
-
Target Type
- Biosimilar
-
Molecular Weight
- 145.5 kDa
-
UniProt
- P78423
Target
-